CD70-targeted CAR-T cell therapy for advanced solid tumors
Treatments studied
Part of Cancer, Hormones & metabolism, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a new treatment using your own immune cells (CAR-T cells) designed to attack cancer cells that have a protein called CD70. It is for people with advanced solid tumors that have not responded to standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- Your tumor must be confirmed to have the CD70 protein (a specific marker).
- Standard treatments like chemotherapy or targeted therapy have stopped working or caused side effects you cannot tolerate.
- You must have at least one measurable tumor on scans (like CT or MRI).
- You should be in fairly good health, with reasonable organ function (heart, kidney, liver, blood counts).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment called CAR-T that targets a protein called CD70 on cancer cells. It is for people with advanced solid tumors that have not responded to or cannot tolerate standard treatments.
This trial tests a lab-made immune therapy (CAR-T) that targets a protein called CD70 found on some advanced cancers. It’s designed for people whose solid tumors have spread and no standard treatments have worked or weren’t tolerated.
This trial tests a new type of immune cell therapy (CAR-T) that targets a protein called CD70 found on some solid tumors. It is for people whose cancer has not responded to other treatments and whose tumor tests positive for CD70. The goal is to see if this treatment can help shrink tumors.
This trial tests a new treatment called CAR-T cells that target a protein called CD70 found on some gynecologic cancer cells. It is for people whose cancer has advanced or spread and has not responded to or stopped responding to standard treatments.
This trial tests a personalized immune-cell treatment (CAR T) built from your own blood lymphocytes. It targets cancers that show a marker called CD70, aiming to slow or stop the cancer when other treatments didn’t work.
This trial tests a new type of immune cell therapy (CAR-NKT cells) that targets a protein called CD70 on cancer cells. It is for people with advanced solid tumors that have not responded to at least two prior treatments.
Hear when a new Renal Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.